儿童风湿科医生对幼年皮肌炎使用Janus激酶抑制剂的治疗路径:CARRA与PReS提供者的调查
该国际调查由CARRA JDM治疗工作组与PReS JDM工作组设计电子问卷,邀请成员填写,共229名应答者(18%),其中150人曾对超过450例JDM患者使用JAKi。77%的用药者报告多数或全部患者临床改善,17%报告副作用;主要障碍为缺乏临床数据和保险审批困难,主要启用指征为难治性皮肤病变、难治性肌肉病变、无法减停激素及对其他保激素药物不耐受。
要点
- 229名应答者中150人曾对超过450例JDM患者超说明书使用JAKi。
- 用药者中77%报告多数或全部患者临床改善,17%报告副作用。
- 主要障碍为缺乏临床数据与保险审批困难;主要指征为难治性皮肤、肌肉病变及激素减停困难。
核心结论
- 儿童风湿科医生超说明书使用JAKi治疗难治性JDM,多数提供者观察到患者临床改善,但缺乏临床数据与保险覆盖是障碍,需要临床试验提供更好的疗效与安全性数据。
研究设计与样本
- CARRA JDM治疗工作组与PReS JDM工作组核心成员设计电子问卷,通过电子邮件邀请CARRA和PReS成员填写,调查JAKi在JDM中的使用情况。
主要发现
- 共229名应答者(18%),其中50%来自美国、29%来自欧洲。
- 150名应答者曾对超过450例JDM患者使用JAKi,其中77%报告多数或全部患者临床改善,17%报告副作用。
- JAKi使用的最高排名感知障碍为缺乏临床数据和无法获得保险审批。
- 启动JAKi的最高排名临床指征为难治性皮肤病变、难治性肌肉病变、无法减停激素和对其他保激素药物不耐受。
临床怎么用
- 原文未据此给出推荐。
局限性
- 应答率为18%。
- 需要临床试验提供JAKi疗效与安全性的更好数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Janus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory JDM. However, JAKi remains an off-label treatment for JDM and there may be variation in use worldwide. An international survey was conducted to investigate approaches to JAKi for JDM. METHODS: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Therapeutics workgroup and core members of the Paediatric Rheumatology European Society (PReS) JDM working party devised an electronic survey to assess the use of JAKi in JDM. CARRA and PReS members were invited by e-mail to complete the survey. RESULTS: There were 229 respondents (18%), with 50% from the USA and 29% from Europe. One hundred and fifty had used JAKi for over 450 patients with JDM; among them, 77% noted clinical improvement in most or all patients and 17% reported side effects. The highest ranked perceived barriers to JAKi use were lack of clinical data and inability to obtain insurance approval. The highest ranked clinical indications for starting JAKi were refractory skin disease, refractory muscle disease, inability to wean steroids and intolerance to other steroid-sparing agents. CONCLUSION: Paediatric rheumatologists use JAKi off-label for refractory JDM. Most providers noted clinical improvement in their patients. Barriers to JAKi use include lack of clinical data and insurance coverage. Clinical trials are needed to provide better data on the efficacy and safety of JAKi.
引用
- Sherman MA, Nicolai R, Datyner EK, et al. Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers. Rheumatology (Oxford). 2025. PMID: 39928372. doi:10.1093/rheumatology/keaf086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。